<p>, /PRNewswire/ -- 药明康德，全球领先的制药合同研发、生产组织（CRDMO），荣获 Frost &amp; Sullivan 颁发的 2025 年全球年度公司奖。这是药明康德连续第九年获得这一殊荣，彰显了公司在推动创新和运营卓越方面的持续成就。</p>
<p>Frost &amp; Sullivan 的认可突显了药明康德 <strong>一体化的端到端 CRDMO</strong> 模式，该模式推动科学和技术进步，使全球客户和合作伙伴能够加速药物开发，并高效地提供变革性疗法。</p>
<p>根据 Frost &amp; Sullivan 的说法，药明康德通过前瞻性的增长战略建立了坚实的科学能力、质量和以客户为中心的敏捷性。公司的统一 CRDMO 模式消除了开发阶段之间的交接，支持价值链的连续性、质量和合规性。通过持续投资于复杂肽、寡核苷酸和新型结合物等下一代技术，药明康德成为生命科学领域创新的催化剂。药明康德在亚洲、欧洲和北美的业务覆盖，能够为从新兴生物科技公司到制药跨国公司等客户提供量身定制的支持，确保快速获取专业知识和全球基础设施，以更快、更高效地将疗法推向市场。</p>
<p>&#34;药明康德的一体化 CRDMO 平台继续重新定义制药生态系统中的战略合作伙伴关系，&#34;Frost &amp; Sullivan 副总裁 Unmesh Lal 表示。&#34;其无缝连接发现、开发和制造的能力使客户能够降低风险、提高效率，并加速商业化时间表。药明康德因将科学深度与运营卓越相结合而脱颖而出，帮助全球创新者将复杂的想法转化为拯救生命的现实。&#34;</p>
<p>&#34;再次获得 Frost &amp; Sullivan 的 2025 年全球年度公司奖是一种荣幸，&#34;药明康德董事长兼首席执行官李革博士表示。&#34;这一认可强调了我们全球团队的承诺，以及我们共同致力于通过一体化 CRDMO 平台帮助客户推进药物的决心。我们将继续专注于我们的核心 CRDMO 战略，以及扩展我们的全球能力和产能，以帮助客户更快、更高效地将改变生命的疗法带给患者。&#34;</p>
<p>每年，Frost &amp; Sullivan 都会向一家在战略发展和实施方面表现出色的公司颁发年度公司认可，结果在市场份额、客户满意度和竞争定位方面取得可衡量的改善。</p>
<p><strong>关于药明康德</strong></p>
<p>药明康德是制药和生命科学行业值得信赖的合作伙伴和贡献者，提供研发和制造服务，帮助推动医疗创新。我们在亚洲、欧洲和北美的运营，通过独特的 CRDMO（合同研发、生产组织）平台提供一体化的端到端服务。我们有幸与来自 30 多个国家的近 6000 个合作伙伴携手合作，支持他们将突破性治疗带给患者。我们坚信每种药物都可以制造，每种疾病都可以治疗，致力于为患者推进突破性进展——一次合作一次进步。了解更多信息，请访问 www.wuxiapptec.com。</p>
<p>来源：药明康德</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMTE5Jk5ld3NJdGVtSWQ9Q04yODY4MiZUcmFuc21pc3Npb25fSWQ9MjAyNTExMTkxOTAwUFJfTkVXU19VU1BSX19fX19DTjI4Njgy?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMTE5Jk5ld3NJdGVtSWQ9Q04yODY4MiZUcmFuc21pc3Npb25fSWQ9MjAyNTExMTkxOTAwUFJfTkVXU19VU1BSX19fX19DTjI4Njgy"/></p>

药明康德

<p>药明康德连续第九年获得 Frost & Sullivan 的 2025 年全球年度公司奖，表彰其在 CRDMO 行业的卓越表现。这一认可突显了药明康德的综合 CRDMO 模式，提升了药物开发和交付的效率。该奖项强调了公司对创新和运营卓越的承诺，支持全球制药的进步</p>

<p>, /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), has been recognized by Frost &amp; Sullivan with the 2025 Global Company of the Year Award in the CRDMO industry. This marks the ninth consecutive year that WuXi AppTec has received this distinguished honor, underscoring the company's ongoing achievements in enabling innovation and operational excellence for its customers.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- 药明康德，全球领先的制药合同研发、生产组织（CRDMO），荣获 Frost &amp; Sullivan 颁发的 2025 年全球年度公司奖。这是药明康德连续第九年获得这一殊荣，彰显了公司在推动创新和运营卓越方面的持续成就。</p>
</div><p>Frost &amp; Sullivan's recognition highlights WuXi AppTec's <strong>integrated, end-to-end CRDMO</strong> model, which drives scientific and technological advancement and enables customers and partners worldwide to accelerate drug development and deliver transformative therapies efficiently.</p>
<div class="lb-trans"><p>Frost &amp; Sullivan 的认可突显了药明康德 <strong>一体化的端到端 CRDMO</strong> 模式，该模式推动科学和技术进步，使全球客户和合作伙伴能够加速药物开发，并高效地提供变革性疗法。</p>
</div><p>According to Frost &amp; Sullivan, WuXi AppTec has established a robust foundation of scientific capability, quality, and customer-focused agility through its forward-looking growth strategy. The company's unified CRDMO model eliminates handoffs between stages of development, supporting continuity, quality, and compliance across the value chain. By continuously investing in next-generation technologies like complex peptides, oligonucleotides and novel conjugates, WuXi AppTec is a catalyst for innovation in the life sciences. With footprint across Asia, Europe, and North America, WuXi AppTec delivers tailored support for customers ranging from emerging biotech firms to pharmaceutical multinationals, ensuring fast access to specialized expertise and a global infrastructure to bring therapies to market faster and more efficiently.</p>
<div class="lb-trans"><p>根据 Frost &amp; Sullivan 的说法，药明康德通过前瞻性的增长战略建立了坚实的科学能力、质量和以客户为中心的敏捷性。公司的统一 CRDMO 模式消除了开发阶段之间的交接，支持价值链的连续性、质量和合规性。通过持续投资于复杂肽、寡核苷酸和新型结合物等下一代技术，药明康德成为生命科学领域创新的催化剂。药明康德在亚洲、欧洲和北美的业务覆盖，能够为从新兴生物科技公司到制药跨国公司等客户提供量身定制的支持，确保快速获取专业知识和全球基础设施，以更快、更高效地将疗法推向市场。</p>
</div><p>&#34;WuXi AppTec's integrated CRDMO platform continues to redefine what strategic partnership means in the pharmaceutical ecosystem,&#34; said Unmesh Lal, Vice President at Frost &amp; Sullivan. &#34;Its ability to seamlessly connect discovery, development, and manufacturing allows clients to reduce risk, improve efficiency, and accelerate commercialization timelines. WuXi AppTec stands out for combining scientific depth with operational excellence, helping global innovators transform complex ideas into life-saving realities.&#34;</p>
<div class="lb-trans"><p>&#34;药明康德的一体化 CRDMO 平台继续重新定义制药生态系统中的战略合作伙伴关系，&#34;Frost &amp; Sullivan 副总裁 Unmesh Lal 表示。&#34;其无缝连接发现、开发和制造的能力使客户能够降低风险、提高效率，并加速商业化时间表。药明康德因将科学深度与运营卓越相结合而脱颖而出，帮助全球创新者将复杂的想法转化为拯救生命的现实。&#34;</p>
</div><p>&#34;It is an honor to again receive Frost &amp; Sullivan's 2025 Global Company of the Year Award,&#34; said Dr. Ge Li, Chairman and CEO of WuXi AppTec. &#34;This recognition underscores the commitment of our global teams and our shared commitment to enabling customers to advance medicines through our integrated CRDMO platform. We will continue to focus on our core CRDMO strategy, and on expansion of our global capabilities and capacity to help our customers bring life-changing therapies to patients faster and more efficiently.&#34;</p>
<div class="lb-trans"><p>&#34;再次获得 Frost &amp; Sullivan 的 2025 年全球年度公司奖是一种荣幸，&#34;药明康德董事长兼首席执行官李革博士表示。&#34;这一认可强调了我们全球团队的承诺，以及我们共同致力于通过一体化 CRDMO 平台帮助客户推进药物的决心。我们将继续专注于我们的核心 CRDMO 战略，以及扩展我们的全球能力和产能，以帮助客户更快、更高效地将改变生命的疗法带给患者。&#34;</p>
</div><p>Each year, Frost &amp; Sullivan presents the Company of the Year Recognition to a company that demonstrates outstanding strategy development and implementation, resulting in measurable improvements in market share, customer satisfaction, and competitive positioning.</p>
<div class="lb-trans"><p>每年，Frost &amp; Sullivan 都会向一家在战略发展和实施方面表现出色的公司颁发年度公司认可，结果在市场份额、客户满意度和竞争定位方面取得可衡量的改善。</p>
</div><p><strong>About WuXi AppTec</strong></p>
<div class="lb-trans"><p><strong>关于药明康德</strong></p>
</div><p>WuXi AppTec is a trusted partner and contributor to the pharmaceutical and life sciences industries, providing R&amp;D and manufacturing services that help advance healthcare innovation. With operations across Asia, Europe, and North America, we offer integrated, end-to-end services through our unique CRDMO (Contract Research, Development, and Manufacturing Organization) platform. We are privileged to work alongside nearly 6,000 partners across 30+ countries, supporting their efforts to bring breakthrough treatments to patients. Guided by our vision that every drug can be made and every disease can be treated, we are committed to advancing breakthroughs for patients—one collaboration at a time. Learn more at www.wuxiapptec.com.</p>
<div class="lb-trans"><p>药明康德是制药和生命科学行业值得信赖的合作伙伴和贡献者，提供研发和制造服务，帮助推动医疗创新。我们在亚洲、欧洲和北美的运营，通过独特的 CRDMO（合同研发、生产组织）平台提供一体化的端到端服务。我们有幸与来自 30 多个国家的近 6000 个合作伙伴携手合作，支持他们将突破性治疗带给患者。我们坚信每种药物都可以制造，每种疾病都可以治疗，致力于为患者推进突破性进展——一次合作一次进步。了解更多信息，请访问 www.wuxiapptec.com。</p>
</div><p>SOURCE WuXi AppTec</p>
<div class="lb-trans"><p>来源：药明康德</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMTE5Jk5ld3NJdGVtSWQ9Q04yODY4MiZUcmFuc21pc3Npb25fSWQ9MjAyNTExMTkxOTAwUFJfTkVXU19VU1BSX19fX19DTjI4Njgy" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=CN28682&amp;Transmission_Id=202511191900PR_NEWS_USPR_____CN28682&amp;DateId=20251119"/></p>

药明康德荣获弗若斯特沙利文 2025 年全球 CRDMO 行业年度公司奖